SOX6 suppresses the development of lung adenocarcinoma by regulating expression of p53, p21 CIPI , cyclin D1 and β-catenin.

Autor: Lv L; Department of Oncology, The First Affiliated Hospital of Harbin Medical University, China., Zhou M; Department of Pathology, The First Affiliated Hospital of Harbin Medical University, China., Zhang J; Department of Thoracic Surgery, The First Affiliated Hospital of Harbin Medical University, China., Liu F; The Sixth Department of Medical Oncology, Harbin Medical University Cancer Hospital, China., Qi L; Department of Radiation Oncology, The Second Affiliated Hospital of Harbin Medical University, China., Zhang S; The Sixth Department of Medical Oncology, Harbin Medical University Cancer Hospital, China., Bi Y; Hemodialysis Department, Heilongjiang Provincial Electric Power Hospital, Harbin, China., Yu Y; The Sixth Department of Medical Oncology, Harbin Medical University Cancer Hospital, China.
Jazyk: angličtina
Zdroj: FEBS open bio [FEBS Open Bio] 2020 Jan; Vol. 10 (1), pp. 135-146. Date of Electronic Publication: 2019 Dec 12.
DOI: 10.1002/2211-5463.12762
Abstrakt: The Sry-related high-mobility group box6 (SOX6) has been implicated in the development of cancer, but its role in lung cancer is incompletely understood. Here, we report that SOX6 expression is frequently down-regulated in lung adenocarcinoma tissues. Moreover, SOX6 can inhibit the proliferation and invasion of lung adenocarcinoma cells, which may occur through cell cycle arrest at G1/S due to up-regulation of p53 and p21 CIPI and down-regulation of cyclin D1 and β-catenin. Univariate and multivariate analyses revealed that the expression of SOX6 is significantly associated with patient disease-related survival and is an independent prognostic factor for lung adenocarcinoma. These data suggest that SOX6 may act as a suppressor of lung adenocarcinoma.
(© 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: